Collegium Pharmaceutical Inc (COLL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Collegium Pharmaceutical Inc stock (COLL) is currently trading at $33.23. Collegium Pharmaceutical Inc PE ratio is 20.49. Collegium Pharmaceutical Inc PS ratio (Price-to-Sales) is 1.44. Analyst consensus price target for COLL is $54.17. WallStSmart rates COLL as Moderate Buy.
- COLL PE ratio analysis and historical PE chart
- COLL PS ratio (Price-to-Sales) history and trend
- COLL intrinsic value — DCF, Graham Number, EPV models
- COLL stock price prediction 2025 2026 2027 2028 2029 2030
- COLL fair value vs current price
- COLL insider transactions and insider buying
- Is COLL undervalued or overvalued?
- Collegium Pharmaceutical Inc financial analysis — revenue, earnings, cash flow
- COLL Piotroski F-Score and Altman Z-Score
- COLL analyst price target and Smart Rating
Collegium Pharmaceutical Inc
📊 No data available
Try selecting a different time range
COLL Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Collegium Pharmaceutical Inc (COLL)
COLL trades at a significant discount to its Graham intrinsic value of $80.96, offering a 44% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Collegium Pharmaceutical Inc (COLL) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, price/sales. Overall metrics suggest strong investment potential with favorable risk/reward.
Collegium Pharmaceutical Inc (COLL) Key Strengths (5)
Keeps $30 of every $100 in revenue after operating costs
Earnings per share surging 31.50% year-over-year
123.35% of shares held by major funds and institutions
Every $100 of equity generates $24 in profit
Paying $1.44 for every $1 of annual revenue
Supporting Valuation Data
Collegium Pharmaceutical Inc (COLL) Areas to Watch (4)
Premium pricing at 3.7x book value
Thin profit margins with limited profitability
Small-cap company with higher risk but more growth potential
Solid revenue growth at 12.90% per year
Collegium Pharmaceutical Inc (COLL) Detailed Analysis Report
Overall Assessment
This company scores 65/100 in our Smart Analysis, earning a B- grade. Out of 9 metrics analyzed, 5 register as strengths (avg 9.4/10) while 4 fall into concern territory (avg 4.8/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on Operating Margin, EPS Growth, Institutional Own.. Valuation metrics including Price/Sales (1.44) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 23.70%, Operating Margin at 30.00%. Growth metrics are encouraging with EPS Growth at 31.50%.
The Bear Case
The primary concerns are Price/Book, Profit Margin, Market Cap. Some valuation metrics including Price/Book (3.74) suggest expensive pricing. Growth concerns include Revenue Growth at 12.90%, which may limit upside. Profitability pressure is visible in Profit Margin at 8.05%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 23.70% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 12.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Operating Margin, EPS Growth) and negatives (Price/Book, Profit Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
COLL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
COLL's Price-to-Sales ratio of 1.44x trades at a deep discount to its historical average of 27.63x (7th percentile). The current valuation is 100% below its historical high of 341.05x set in Dec 2017, and 20% above its historical low of 1.2x in Jul 2019.
Compare COLL with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Collegium Pharmaceutical Inc (COLL) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Collegium Pharmaceutical Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 781M with 13% growth year-over-year. Profit margins are thin at 8.1%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
ROE of 2370.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 122M in free cash flow and 123M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Collegium Pharmaceutical Inc push profit margins above 15% as the business scales?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Collegium Pharmaceutical Inc.
Bottom Line
Collegium Pharmaceutical Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(21 last 3 months)
| Insider | Type | Shares |
|---|---|---|
DIETER, DAVID EVP & General Counsel | Sell | -6,224 |
Data sourced from SEC Form 4 filings
Last updated: 8:24:12 AM
About Collegium Pharmaceutical Inc(COLL)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.